|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, our results indicate that the naturally occurring 19305DP-TCR derived from CD4<sup>+</sup>CD8<sup>+</sup> double-positive αβ T cells, is a promising therapeutic TCR gene for effective and safe adoptive T-cell therapy in A*02<sup>+</sup> patients with NY-ESO-1-expressing tumor.
|
30626427 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of TWIST1 and NY-ESO1 mRNA was observed in 42% and 39.5% (P ˂ 0.05) of tumors, respectively.
|
31158427 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adults with previously treated, advanced, NY-ESO-1-positive solid tumors and limited tumor burden were eligible.
|
31227504 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings implied the potential role of NY-ESO-1 in tumor immune escape of NSCLC and indicated the requirement to remove Treg cells in TCR-T cell therapy for NSCLC patients.
|
30953385 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
With the exploration of specific tumor antigens such as NY-ESO-1, which is expressed in ovarian carcinoma and other malignancies, the development of therapeutic cancer vaccines has been pursued initiating the era of personalized anti-cancer medicine.
|
30640705 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We identified a candidate TCR, TCR-3598_2, which was expressed in CD4+ T cells and caused tumor regression in combination with NY-ESO-1-redirected CD8+ T cells in a mouse model of adoptive T cell therapy.
|
30530988 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results indicate that vaccination with a tumor-associated peptide is able to boost NY-ESO-1-specific, functionally active T cells in advanced neuroblastoma patients with lymphocyte infiltration in their pre-vaccine tumors.
|
30326856 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Antigen MAGE-A10 demonstrated a significant association with higher expression of ER (P=0.005) and higher tumor nuclear grade (P=0.001), cytoplasmic staining (P=0.029) and antigen NY-ESO-1 with higher tumor size (P=0.001), expression of TILs (P=0.001) and R1 resection (P=0.001).
|
30546463 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therefore, in planning clinical trials of MAGE-A4 vaccine, enrolling NY-ESO-1-expressing tumor or not would be a critical issue to be discussed.
|
30542513 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NY-ESO-1 positivity, as a surrogate for a preexisting immune response against tumour antigens, might help identifying patients with a superior outcome from immune checkpoint blockade.
|
29306769 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
NY-ESO-1 was the only differentially expressed antigen and was absent in ER+ and ER-PgR + tumors, as for an exclusive expression of either NY-ESO-1 or at least one hormonal receptor (HR+).
|
30189381 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
KK-LC-1 was expressed in 80% of tumor samples, markedly higher than melanoma antigen gene (MAGE)-A1, MAGE-A3, MAGE-A4, synovial sarcoma, X breakpoint 4 (SSX4) and New York esophageal squamous cell carcinoma-1 (NY-ESO-1).
|
28438869 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunization with NY-ESO-1 antigen plus alum-CpG-HH2 combinatorial adjuvant effectively inhibited tumor growth and reduced tumor burden in prophylactic and therapeutic tumor models and even in passive serum or cellular therapy.
|
28515346 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The serum NY-ESO-1 antibody was detected in 18.4% of patients with intrahepatic cholangiocarcinoma, a value that was significantly higher than that in patients with chronic Hepatitis B. Serum NY-ESO-1 antibody was positively correlated with tumor differentiation, lymphatic metastasis, cTNM stage and abdominal pain.
|
29262561 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Patients with squamous cell carcinoma displayed higher expression of NY-ESO-1 and MAGE-A4 in tumors than did patients with adenocarcinoma.
|
27793776 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combined use of MAGEA4 and NY-ESO-1 increased the sensitivity, specificity, positive predictive values, and negative predictive values for distinguishing synovial sarcoma from spindle cell tumors and other mimicking tumors, compared to individual use of MAGEA4 or NY-ESO-1.
|
28744588 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Spontaneous T-cell immunity against CTAg proteins therefore develops in many patients with testicular cancer and may play an important role in the excellent clinical outcome of patients with this tumor subtype.
|
28555838 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NY-ESO-1-specific CD4(+) T cells are of interest for immune therapy against tumors, because it has been shown that their transfer into a patient with melanoma resulted in tumor regression.
|
26608910 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Materials Methods: Using a comprehensive tissue microarray (TMA) of both benign and malignant tumors in primary, recurrent, and metastatic samples, we examined NY-ESO-1 expression in peripheral nerve sheath tumor (PNST) and adipocytic tumors.
|
27655679 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results demonstrated higher expression of MAGE-A compared with NY-ESO-1 in melanomas (32% vs. 13%) and squamous cell carcinomas (45% vs. 7.9%), and higher expression of both CTAs in metastatic versus primary tumors.
|
26641256 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also tested the impact of combined SGI-110 and NY-ESO-1-specific CD8+ T-cells on tumor growth and/or murine survival in a xenograft setting.
|
25793777 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The detection and quantification of single NY-ESO-1 peptides presented at the tumor cell surface in the context of HLA-A*0201 molecules revealed an increase of 100% and 50% for MCF7 and U266 cells, respectively.
|
26447882 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also demonstrate that blockade of Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) during vaccination enhances the frequency of NY-ESO-1-specific effector CD8(+) T cells producing IFN-γ and promotes lymphocyte migration to the tumor infiltrate.
|
25403749 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The high expression levels of MAGE-A1, MAGE-A3, and NY-ESO-1 were sustained in sarcoma lines and primary tumor lines over 30 days after the cessation of DAC.
|
24584817 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Increased NY-ESO-1 serum antibodies and T cell responses were observed in the majority of patients, and antibody spreading to additional tumor antigens was also observed.
|
24535937 |
2014 |